Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen

Eur J Cancer. 1994;30A(6):894-5. doi: 10.1016/0959-8049(94)90318-2.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Erythropoietin / therapeutic use*
  • Female
  • Hemolytic-Uremic Syndrome / therapy*
  • Humans
  • Middle Aged
  • Mitomycin / adverse effects
  • Tamoxifen / adverse effects

Substances

  • Tamoxifen
  • Erythropoietin
  • Mitomycin